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Abstract: Rhabdomyosarcoma is subclassified by the presence or absence of a recurrent
chromosome translocation that fuses the FOXO1 and PAX3 or PAX7 genes. The fusion protein
(FOXO1-PAX3/7) retains both binding domains and becomes a novel and potent transcriptional
regulator in rhabdomyosarcoma subtypes. Many studies have characterized and integrated genomic,
transcriptomic, and epigenomic differences among rhabdomyosarcoma subtypes that contain the
FOXO1-PAX3/7 gene fusion and those that do not; however, few investigations have investigated
how gene co-expression networks are altered by FOXO1-PAX3/7. Although transcriptional data
offer insight into one level of functional regulation, gene co-expression networks have the potential
to identify biological interactions and pathways that underpin oncogenesis and tumorigenicity.
Thus, we examined gene co-expression networks for rhabdomyosarcoma that were FOXO1-PAX3
positive, FOXO1-PAX7 positive, or fusion negative. Gene co-expression networks were mined
using local maximum Quasi-Clique Merger (lmQCM) and analyzed for co-expression differences
among rhabdomyosarcoma subtypes. This analysis observed 41 co-expression modules that were
shared between fusion negative and positive samples, of which 17/41 showed significant up- or
down-regulation in respect to fusion status. Fusion positive and negative rhabdomyosarcoma showed
differing modularity of co-expression networks with fusion negative (n = 109) having significantly
more individual modules than fusion positive (n = 53). Subsequent analysis of gene co-expression
networks for PAX3 and PAX7 type fusions observed 17/53 were differentially expressed between the
two subtypes. Gene list enrichment analysis found that gene ontology terms were poorly matched
with biological processes and molecular function for most co-expression modules identified in this
study; however, co-expressed modules were frequently localized to cytobands on chromosomes 8 and
11. Overall, we observed substantial restructuring of co-expression networks relative to fusion status
and fusion type in rhabdomyosarcoma and identified previously overlooked genes and pathways
that may be targeted in this pernicious disease.
Keywords: rhabdomyosarcoma; gene fusion; gene co-expression analysis; quasi-clique merger; copy
number variation
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1. Introduction
1.1. Gene Fusions in Solid Tumors
Gene fusion is an important consequence of mutation that has been observed in many cancers
including malignant solid tumors, leukemia, and especially pediatric sarcoma [1,2]; such fusions may
be drivers of, or contribute to cancer progression. Advances in next generation sequencing technologies
have empowered a new generation of genomic, transcriptomic, and epigenetic studies of different
cancers, and such studies have highlighted the prevalence of structural variation that lead to gene
fusions. Recent studies have underscored the important functional roles of gene fusions in sarcoma
biology with the promise of providing insights that lead to treatment and improved prognosis. As an
example, rhabdomyosarcoma frequently contain recurrent gene fusions involving FOXO1 genes and
PAX genes amid a changing landscape of genome mutations and structural variations [3]. The presence
of gene fusions reduces patient prognosis because they are associated with aggressiveness of the
tumors. While some differential expression analyses have been conducted for gene fusions in pediatric
sarcomas [4], relatively few systems biology analyses have been conducted for gene fusions in pediatric
sarcomas. The goal of this paper is to implement a systems biology approach for the FOXO1-PAX3/7
fusion in rhabdomyosarcoma using gene correlation network analysis to infer novel biological insights
and hypotheses about this aggressive pediatric cancer.
1.2. Rhabdomyosarcoma and the FOXO1-PAX3/7 Fusion
Rhabdomyosarcoma is an aggressive malignancy of soft-tissue that may occur in any non-boney
tissue but predominantly arises from striated muscle or myogenic progenitors [5–10]. It is a pediatric
cancer with most cases occurring in young patients rather than adults [5–10]. Rhabdomyosarcoma may
occur in a diverse range of tissues, several subtypes of which are recognized based on histopathology
and presentation of the disease, including botryoid embryonic, spindle embryonic, alveolar, and
anaplastic [5,11]. In the aggressive alveolar-type rhabdomyosarcoma, a translocation occurs in the
majority of patient cases that results in a fusion of fork-head box 1 (FOXO1) and paired box 3 or
paired box 7 (PAX3/7) genes [12,13]. The presence of this fusion has been associated with differences in
epigenetic regulatory elements [4,14–17], chromatin content and instability [3,18], copy number variance
and structural variation [3,19,20], and gene expression [4,21–23]. FOXO1-PAX3/7 fusion positive tumors
have higher mortality fusion negative, and diagnosis can lead to improved risk stratification ([24–26],
but see [27]). FOXO1 and the PAX complex of genes encode transcriptional regulation proteins for cell
cycle, growth, and development, and their biology may be an important component of FOXO1-PAX3/7’s
effects. It is important to note that the histopathological subclassification of rhabdomyosarcomas may
be confounded by molecular differences and vice versa. Classically, alveolar rhabdomyosarcoma are
differentiated into FOXO1-PAX positive vs. negative; however, embryonic rhabdomyosarcoma are
sometimes included with fusion negative alveolar rhabdomyosarcoma, and there is some evidence that
these subtypes are indistinguishable clinically [16]. Here, we adopt fusion negative and fusion positive
terminology that denotes the presence or absence of FOXO1-PAX3/7 and is agnostic to histopathological
designation as the presence or absence of the fusion is integral to understanding how it may change
gene correlation networks.
The fusion protein (FOXO1-PAX3/7) contains the activation domain of FOXO1 and full binding
domain of PAX3 or PAX7 ([12], reviewed in [28]). DNA binding domains are retained in the
fusion protein, which promotes DNA binding and altered gene expression. The fusion protein
is expressed and shows strong effects on transcriptional regulation such as (1) PAX3/7 promoted
transcription sites become expressed when otherwise silenced early in development; (2) expression is
amplified; and (3) the fusion protein localizes to the nucleus ([12], reviewed in [28]). In combination,
FOXO1-PAX3/7 becomes a potent transcription regulator that induces downstream changes in gene
expression for multiple pathways, including PAX3/7 targets involved in myogenic differentiation,
interference with normal FOXO1-signaling, cellular proliferation, apoptosis, and the interplay among
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them [7,12,17,28–34]. Presence of the fusion protein alone is insufficient to cause oncogenesis, but it
contributes to tumorigenicity and pathogenesis ([28,29] but see [35]).
1.3. Gene Co-Expression Networks and Rhabdomyosarcoma
Many studies have documented changes in gene expression with respect to FOXO1-PAX3/7,
including high-throughput expression arrays, manipulation FOXO1-PAX3/7 expression in animal
models and cell lines, and integrated -omics based approaches [4,12,15,16,21,23,28]. These studies
identified key pathways and processes in rhabdomyosarcoma that may be targeted in treatment,
RAS/MEK/ERK pathway in particular [3,6,15,36]. Recently, Sun et al. [4] conducted a comparison of
methylation patterns and gene expression for rhabdomyosarcoma with and without FOXO1-PAX3/7.
They observed 548 up- and 454 down-regulated genes in FOXO1-PAX3/7 fusion positive samples
based on differential expression analysis and a minimum absolute fold change larger than 2. While
differential analysis can reveal how gene expression is affected by fusion status, it is often difficult to
infer key biological processes or events without also accounting for the relationships among genes.
More importantly, co-expression network analysis can identify statistical associations among genes
that have not been previously identified by targeted studies and reduce complexity for better biological
inference. Inferring both core and differential biological processes by examining their correlations
among expressed genes will almost certainly lead to new hypotheses for these rare, understudied
cancers and their molecular subtypes.
1.4. Study Overview
For the above reasons, we examined gene co-expression networks in rhabdomyosarcoma with
respect to the presence or absence of the FOXO1-PAX3/7 fusion. Gene co-expression network analysis
has been widely adopted in bioinformatics to infer gene relationships, predict new gene functions,
discover important biological processes, and identify biomarkers for diseases [37–42]. Each gene
is treated as a node and among gene correlation coefficients—or a transformation of them—can be
calculated and used to weight edges linking genes in the network. Such networks may be mined to
define clusters of genes with especially strong co-expression, defined as gene modules and summarized
as eigengenes, and enable discovery of genes with highly correlated expression in different conditions.
Strongly correlated gene modules within correlation networks often share common biological functions
or regulation, e.g., participating in the same biological process or pathway and/or co-regulated by
the same transcription factors. The biological implications of gene co-expression modules can often
be inferred from gene ontology enrichment analysis. In addition, gene module co-expression can be
used for comparative analysis among network modules or in response to different conditions with
much greater statistical inference; e.g., in response to fusion status and type. With these potential
advantages, we examined the gene correlation networks of gene expression microarrays from the
Sun et al. [4] study of fusion negative, FOXO1-PAX3 positive, and FOXO1-PAX7 samples. We identified
and compared gene correlation networks as a response to the presence/absence and type of fusion for
rhabdomyosarcomas. We hope this translational bioinformatics study leads to new insights about the
underlying systems biology, as well as a confirmation of existing knowledge about this pernicious
pediatric disease.
In addition to being functionally related, co-expressed genes could also reside on the same
cytoband of a chromosome. This is particularly common in cancer samples. Such enrichment of
co-expressed genes on specific cytobands often implies copy number variation (CNV) events on these
cytobands among the patients. Due to structure proximity, expression levels of genes affected by the
same CNV event can be correlated. Given the prevalence of CNV events in cancers, we can also take
advantage of gene co-expression network mining to identify potential CNV events. We compared gene
co-expression modules that were differentially expressed relative to fusion with CNV information from
four new rhabdomyosarcoma cases at Riley Children’s Hospital (Indianapolis, IN, USA). We observed
that co-expression modules overlapped significantly with genes that also had copy number variants,
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especially those observed in patients that were FOXO1-PAX3/7 negative. These fusion positive patients
harbored fewer copy number variants, whereas fusion negative harbored many, which was consistent
with previous studies of copy number variance in rhabdomyosarcoma [3,6,8,15,18].
2. Materials and Methods
2.1. Data Source and Pre-Analysis Processing
Gene expression data of rhabdomyosarcoma tissue from 25 patients with fusion-negative type,
26 patients with FOXO1-PAX3 type, and 7 patients with FOXO1-PAX7 type were obtained from NCBI
Gene Expression Omnibus (GSE #66533). The determination of fusion status and type are described
by Sun et al. [4] and details therein [43]. GEO data was downloaded as robust multiarray average
(RMA) normalized probe expression values from an Affymetrix GeneChip Human Genome U133 Plus
2.0 microarray (Thermo Fisher Scientific Inc., Waltham, MA, USA). Gene expression series data were
imported into R using the GEOquery package [44] from BioConductor [45].
The raw data contained 54,675 probes mapped to ~35,000 gene symbols; however, multiple probes
were matched to the same gene. Probes without gene symbols were removed, and the maximum
probe value was used as the gene expression value. Co-expression analysis is based on gene-by-gene
regressions which require variance and covariance for meaningful inference [42,46]. For this reason,
the genes with expression variance in the bottom 33% quantile were removed to reduce noise in
the co-expression analysis and reduce computational demands while retaining many genes for gene
co-expression network (GCN) analysis (n = 15,759).
2.2. Gene Co-Expression Network Analysis
All data manipulation and statistical methods were performed using R version 3.5.1 [47] and R
packages (described below). Gene co-expression network analysis was performed with local maximum
Quasi-Clique Merger (lmQCM), using the R package lmQCM [46]; for theory and background
see [41,42,46,48]. lmQCM analysis was implemented with γ = 0.7, and correlation matrices were
calculated using Spearman Rank correlation coefficient.
2.3. Relating Co-Expression Module Expression Variance and Fusion Status
The aim of co-expression analysis was to identify co-expressed gene modules that differed with
respect to fusion positive and fusion negative samples. To identify which co-expression modules had
differential expression with respect to fusion status, we performed principal component analysis and
subsequently analyzed projected loading values using permutational analysis of variance with fusion
status (positive vs negative and PAX3 vs. PAX7) as an explanatory variable. First, principal components
analysis was performed separately for each co-expression module and sample loading values were
calculated for each principal component. In this analysis, the first principal component represented the
axis of greatest gene expression variation for each module. Next, the among sample distance matrix
of loading values were calculated and treated as a response variable using permutational analysis
of variance with fusion status as an explanatory variable using the adonis function from the vegan
package for R [49]. Co-expression modules were considered as associated with fusion status and
type differences when p < 0.05. This analysis probes the degree to which gene expression variance is
explained by fusion status of co-expressed modules common to all rhabdomyosarcoma samples, i.e.,
differential expression is implied by a significant effect of fusion status.
A key difference between lmQCM and other gene co-expression network algorithms is that it
allows genes to belong to multiple co-expressed modules, i.e., gene overlap is permitted. Genes that are
merged into multiple modules may represent genes that integrate related but interactively distinct gene
interaction networks. Thus, gene overlap among the 4 largest upregulated and 4 largest downregulated
co-expression were identified and described to identify genes that link co-expressed modules.
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Gene co-expression analysis was performed on fusion negative and fusion positive samples
separately to compare overall metrics of network structure: module count and size. Because fusion
positive samples were potentially confounded by two unique PAX fusion types with unique GCNs,
fusion positive samples were secondarily investigated for differential co-expression between PAX3 and
PAX7-type fusions (See Section 2.2 for details). While not a primary aim of the manuscript, we observed
that several co-expression modules were differentially regulated between the two fusion types.
2.4. Functional Enrichment Analysis
Modules that showed an association between expression variance and fusion status were
subsequently analyzed for functional enrichment and co-expression atlas using ToppFunn (https:
//toppgene.cchmc.org/). Gene ontology (GO), cytoband analysis, and co-expression atlas terms that were
considered statistically significant if the false discovery rate (FDR) <0.05. In addition, we performed
pathway analysis using Ingenuity® Pathway Analysis (https://www.qiagenbioinformatics.com/) from
QIAGEN, Inc. (Venlo, The Netherlands) for gene modules that were significantly associated with
PAX3 and PAX7 differences from fusion positive network analysis. This was performed in addition to
ToppFunn enrichment analysis because these gene modules had low affinity for specific biological
processes and co-expression atlas annotations, and such an analysis can highlight additional information
about identified gene networks.
2.5. Copy Number Variation in Rhabdomyosarcoma
Four rhabdomyosarcoma cancer samples were sequenced using Illumina platform with the data
processed using the BWA-SAMBLASTER-GATK pipeline. This analysis generated a VCF file that
included copy number alteration and breakpoint coverage for rhabdomyosarcoma samples. Based on
the structural variation data, one of the four samples harbored the FOXO1-PAX3 gene fusion. Based on
the copy number alteration data, a circular binary segmentation (CBS) analysis was performed using
the R package DNAcopy [50]. Segments were mapped to reference hg19 genome assembly. Gene-level
copy number variation (CNV) was estimated using the GISTIC2 method [51]. Genes were categorized
as having copy number variation based on when CNV ≥ 0.2 or ≤ 0.2. Genes with CNV values ≤ 0.2
were categorized as deletion and ≥ 0.2 were categorized as amplifications (based on [52]).
The list of genes with significant copy number variation from both fusion negative and positive
samples were compared with the genes mapped into co-expression modules (see above). Counts of
gene overlap were analyzed using Fisher’s exact test and a p < 0.05 for statistical significance.
3. Results
3.1. Consensus Network Analysis of Fusion-Associated Module Expression Patterns
lmQCM consensus network analysis identified 41 gene co-expression modules that were shared
in fusion negative and positive samples (Table S1). A subset of these modules had a statistically
significant relationship between fusion status and gene co-expression patterns (Figure 1, Table 1).
4/17 modules contained upregulated genes in FOXO-PAX3/7 positive samples, whereas 13/17 contained
downregulated genes (Figure 1 and Figure S1).
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4 459 0.001
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Modules 3, 24, 34, and 40 showed elevated expression values in FOXO1-PAX3/7 positive samples
compared to fusion negative (Figure 1). There was limited overlap among the gene names for these
4 co-expression modules, especially compared with fusion negative networks (Figure 2). 5/17 genes
from module 24 and 3/12 genes from module 34 were co-expressed in module 3; however, no other
overlaps for these modules were observed (Figure 2A). Overlap genes in modules 3 and 24 were PROX1,
CD82, PGBD5, SCN4A, and LINC00689; overlap genes in modules 3 and 34 were BMS1P6, BMS1P5, and
RP11-235E17.4. Of these genes, several may be important for rhabdomyosarcoma, including a homeobox
transcription factor (PROX1), a tumor suppressor (CD82), a transposable element (PDBD5), a muscle
sodium channel (SCN4A), and a long intergenic non-coding RNA (LINC00689) (see Discussion).
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3.2. Gene Ontology, Cytoband, and Co-Expression Atlas
Gene names from modules associated with fusion status were submitted to ToppGene functional
enrichment analysis. The top gene ontology term and cytoband location for each module are reported
in Table 2. Many of the modules did not match to specific gene ontology functions and only 8/17
co-expression modules had statistically significant GO ter mapping (Table 2 and Table S2). Gene
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module 3, which was upregulated in fusion positive samples, returned no biological processes as
enriched. Genes from this module were significantly localized to cytobands on chromosomes 9, 10,
and 16. In contrast, downregulated modules 4, 5, 9, and 10—all downregulated in fusion positive
samples—returned biological process enrichments for RNA processing, developmental pathways, and
Golgi-related pathways. Modules 4, 5, and 9 were strongly associated with cytobands on chromosomes
8 and 11, while module 10 showed localization to chromosome 19.
Table 2. Gene list enrichment analysis of biological processes and cytoband locations 5 largest
differentially co-expressed gene modules in fusion negative and fusion positive samples (See Table S2
for all differentially co-expressed modules). Module 3 was upregulated, whereas Modules 4, 5, 9, and
10 were downregulated.
Module GO ID Biological Process FDR B&Y Cytoband FDR B&Y
3 NA NA NA | 9q21.11 <0.0001
| 16p12.3 <0.0001
| 16p12.2 <0.001
| 10q26 <0.001
4 6369 RNA Processing <0.0001 | 8q24.3 <0.0001
34660 ncRNA metabolic process <0.0001 | 11q13 <0.0001
34470 ncRNA processing <0.0001 | 11q21 <0.0001
22613 ribonucleoprotein complex biogenesis <0.0001 |
|
8q24.13 <0.0001
70647 protein conjugation by conjugation or removal <0.0001 |
|
8p21.3 <0.001
5 9790 embryo development <0.0001 | 11q13 <0.001
35295 tube development <0.0001 | 11q21 <0.001
31175 neuron projection development <0.0001 |
|
11p15.3 0.012
22008 neurogenesis <0.0001 | 7q21 0.046
45595 regulation of cell differentiation <0.0001 |
|
9 6890 retrograde vesicle transport <0.0001 | 11q13 <0.0001
48193 Golgi transport <0.0001 | 11p15.3 <0.0001
6888 ER to Golgi vesicle transport <0.0001 | 11q12.2 <0.001
30968 endoplasmic reticulum unfolded protein <0.001 |
|
11p15.5-4 <0.01
6986 response to unfolded protein <0.001 | 11p12-p11 <0.01
10 6396 RNA Processing <0.01 | 19p13.3 <0.0001
22613 ribonucleoprotein complex biogenesis <0.01 |
|
19p13.11 <0.0001
NA NA NA | 19p13.2 <0.0001
| 19p13.32 <0.01
Co-expression modules that did not return results from gene enrichment analysis were labeled with the abbreviation
“NA” for not available. Processes reported do not directly correspond to cytoband locations reported.
Co-expression Atlas enrichment analysis revealed that co-expression modules contained genes
with known differential regulation due to FOXO1-PAX3/7 fusion and annotations related to cancer
more generally (Table 3 and Table S3). Module 3 returned annotations are defined as genes upregulated
in rhabdomyosarcoma that harbor or commonly contain the FOXO1-PAX3/7 fusion and 1 annotation
that contains genes downregulated with FOXO1-PAX3/7 is knocked down in cell lines. Module 5
returned annotations that are commonly downregulated when the FOXO1-PAX3/7 fusion is present.
Interestingly, genes annotated as developmental or related to stem cells were observed among most
co-expression modules, and module 4 contained annotations suggesting broader connections to cancer.
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Table 3. Top results of ToppGene co-expression analysis for the 5 largest co-expressed modules
identified by consensus lmQCM analysis (See Table S3 for more detailed table).
Module Input # ID Name p
3 576 M2012
Genes up-regulated in alveolar
rhabdomyosarcoma compared to
embryonic rhabdomyosarcoma
p < 0.0001
4 475 15902281—Table S1A Human Leukemia Schoch05 p < 0.0001
5 326 M8519
Genes down-regulated in alveolar
rhabdomyosarcoma compared to
embryonic rhabdomyosarcoma
p < 0.0001
9 121 15902281—Table S1B Human Leukemia Schoch05 p < 0.0001
10 80
FacebaseRNAseq e8.5 Hind Brain
Neural Epithelium
top-relative-expression-ranked 2500
k-means-cluster#2
p < 0.0001
3.3. lmQCM of Fusion Negative and Fusion Positive Gene Co-Expression Networks
We performed lmQCM network analysis on gene expression data on FOXO1-PAX3/7 positive and
negative samples separately to assess the degree to which network modularity was affected by fusion.
This identified 53 co-expression modules in FOXO1-PAX3/7 positive samples that contained a median
of 17 and mean of 138.9 genes. 109 co-expression modules were identified in fusion negative samples
with a median of 13 and mean of 70.4 genes. Unexpectedly, several of the co-expression modules
from the fusion positive gene correlation network were differentially co-expressed PAX3- versus
PAX7-type fusion positive samples (Figure 3). As with consensus network analysis, modules-of-interest
were sorted using PCA and permutational Anova analysis. For 17/53 co-expression modules, fusion
status—but here, PAX3 vs PAX7 type fusions—caused differential regulation of co-expressed gene
modules (Table 4 and Table S4).
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Figure 3. Gene expression heatmaps of co-expression modules that were identified from lmQCM
network analysis of FOXO1-PAX3/7 positive samples and that showed differential gene regulation
between PAX3 and PAX7 cases. Expression values were organized by hierarchical clustering to better
visualize absolute expression values (left). To see potential differences between PAX3 and PAX7 type
fusions, gene expression values were normalized (right).
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Table 4. Differential co-expression analysis of modules that were significantly different in PAX3 vs
PAX7 fusion positive patients. For brevity, only modules with significant (p < 0.05) differences are
reported (see Table S4 for full results).
Module Gene Count p
5 178 0.002
7 148 0.006
9 84 0.016
10 72 0.002
11 62 0.001
15 37 0.004
17 32 0.038
24 19 0.03
25 18 0.001
26 18 0.011
28 16 0.015
33 14 0.001
36 13 0.001
39 12 0.004
41 11 0.008
44 11 0.022
47 10 0.045
50 10 0.05
We further examined the co-expression modules that were differentially regulated between PAX3-
and PAX7-type and observed that FOXO1 appeared in modules 7 and 10, which were differentially
upregulated in PAX7 fusions. These genes had expression values that were ~2× higher in PAX7-
versus PAX3-type fusions. In contrast to FOXO1-PAX3 type fusions, FOXO1-PAX7 fusions did not
associate with co-expression annotations related to prior rhabdomyosarcoma studies when queried
using gene enrichment analysis. To better understand how FOXO1 signaling within these co-expression
modules may drive network-level differences in PAX7-type, we implemented Ingenuity Pathway
Analysis to map known and inferred relationships among these key genes in the presence of the
FOXO1-PAX7 fusion (Figure 4). This analysis revealed that the PAX7-specific fusion was associated
with an upregulation of BCL2—a critical component of apoptosis (Figure 4A).
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Figure 4. The network visualization of pathway analysis for modules 7 (A) and 10 (B) from fusion
positive network analysis. All genes were upregulated in PAX7 samples compared to PAX3; however,
the degree to which genes were upregulated varied. Genes with green coloration had higher log2-fold
change. Solid lines indicate a direct relationship between two genes, whereas dashed lines indicate an
indirect predicted relationship. FOXO1 and PAX7 were important genes for both modules and showed
2-fold and 3-fold increase respectively in PAX7 samples.
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3.4. Copy Number Variation
We performed whole genome sequencing on four rhabdomyosarcoma samples. One sample was
positive for the FOXO1-PAX3/7 gene fusion, and three samples were negative. Copy number variation
analysis using a log change value >0.2 resulted in 306 amplifications and 239 deletions for the fusion
positive sample. The fusion negative samples had 8746, 7883, 6514 amplifications and 8284, 4214,
1565 deletions, respectively.
3.5. Copy Number Variation in Gene Modules from Consensus Network
We examined whether genes with CNV were clustered into one or more co-expression modules
from consensus network analysis by comparing overlap. Few co-expression modules with differential
expression showed overlapping copy number variation. However, co-expression modules 4 and 5
each had a statistically significant count of genes that also have significant CNV (Table 5). These gene
expression modules were significantly associated with multiple cytobands on chromosomes 8 and 11
(Table 2).
Table 5. Count overlap of genes with significant copy number variation and consensus lmQCM
co-expression modules that showed statistically significant association with fusion status.
Module Total Gene Count Genes with CNV p
3 576 37 0.657
4 459 157 <0.0001
5 334 44 <0.0001
9 118 10 0.241
10 84 4 0.819
15 33 4 0.132
19 24 0 0.398
23 17 0 0.621
24 17 1 1
27 15 0 1
31 13 0 1
34 12 0 1
35 11 0 1
36 11 0 1
38 10 1 0.46
39 10 0 1
40 10 1 0.46
41 10 0 1
Statistical values reported from Fisher’s Exact Test.
4. Discussion
We observed co-expressed gene modules that were also differentially regulated with respect to
fusion status in rhabdomyosarcoma. Many of the genes that were co-expressed in these modules have
been implicated in previous studies of differential expression analyses ([4], especially [22]). Congruence
between existing differential expression studies and this network analysis help validate the patterns
described and discussed in this study. For example, module 3 contained 139/331 genes upregulated
in alveolar compared to embryonic rhabdomyosarcoma, 27/48 genes that were downregulated when
FOXO1-PAX3 was altered with RNA interference, and 22/64 genes previously associated with cell line
differences related to PAX3 and PAX7 fusions (Table 4 and Table S4). Module 5 contained 75/182 genes
that were downregulated in alveolar versus embryonic, and 50/408 genes that were downregulated
when FOXO1-PAX3 was overexpressed in mouse models. Because co-expression analysis identifies
correlations among genes, genes that have differential expression, but are not strongly correlated
with large modules, are not considered here. This could explain why some annotated genes were
missing from gene co-expression modules identified in the current study. However, co-expressed
genes that were not identified in previous investigations—perhaps due to selection criteria, restrictions
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of gene expression information, or because relationships among genes were not accounted for—may
harbor undiscovered FOXO1-PAX3/7 genes and pathways, which in turn may contain novel targetable
pathways for rhabdomyosarcoma.
Many of the gene co-expression modules from consensus analysis also matched with
developmental, stem cell, and cancer genes. Modules 4 and 9 contained genes related to leukemia and
hepatoblastoma and had significant mapping to chromosomes 8 and 11 (Tables 2 and 3, Tables S2 and S3).
These results suggest that FOXO1-PAX3/7 positive rhabdomyosarcoma show differential expression
for genes that are broadly co-expressed in cancers, perhaps representing core growth and proliferative
pathways common to oncogenesis. Interestingly, gene enrichment analysis returned developmental
and stem cell genes, based on annotations from Davicioni et al. [22]. PAX genes are normally a
component of embryogenesis, and recent studies have explored the relationship between PAX fusions,
myogenic differentiation, and muscular phenotypes common in rhabdomyosarcoma [4,6,15–17]. These
studies have described in detail how activation of myogenic transcription factors downstream of
PAX, as well as methylation status combine to elucidate the manners in which biological patterns
determined by functional mechanisms in rhabdomyosarcoma subtypes. Thus, co-expression modules
from our gene correlation network analysis recapitulate known biological phenotypes and mechanisms
underlying rhabdomyosarcoma.
A potentially important phenomenon for modeling gene interaction networks is that some genes
may interact for two or more co-expression modules. lmQCM is quite different from other gene
co-expression network mining algorithms in that it can assign a gene to multiple co-expression modules,
which is not the case for hierarchical-based module detection. This helps identify the degree to which
different co-expression modules are integrated vs dis-integrated in different conditions. For example,
we observed different degrees of overlap in downregulated versus upregulated co-expression modules
that were also differentially expressed in fusion negative and fusion positive samples. Upregulated
genes tended to act more cohesively as a network with one large module and few small modules that
showed low to moderate overlap. This result suggests that co-expression patterns of upregulated
genes were driven by stronger correlations that were merged by the lmQCM algorithm.
Importantly, investigating which genes belong to multiple modules may lead to important
new biological insights that have been neglected or overlooked by studies that do not permit
gene membership in multiple modules. Co-expressed, upregulated genes that were members of
multiple modules included a homeobox transcription factor (PROX1), a tumor suppressor (CD82),
a transposable element (PDBD5), a muscle sodium channel (SCN4A), and a long intergenic non-coding
RNA (LINC00689). Downregulated modules had co-expression modules with substantially more
overlap than upregulated genes (Figure 2). Genes that overlapped with 3 of the 4 largest downregulated
modules were identified and included oncogenic genes, e.g., TMEM138, as well as externally mediated
apoptosis, e.g., FADD (Figure 2). FADD is a particularly important gene to identify in this analysis
because it mediates FAS-associated cell death and is downregulated along with 3 somewhat distinct
co-expression modules. A prior study documented resistance to FAS-mediated cell death in alveolar
rhabdomyosarcoma cell lines and proposed that targeting the FAS-pathway may lead to treatments for
rhabdomyosarcoma with gene fusion [53]. Our analysis rediscovered FADD.
It is worthwhile to point out that we also tested the widely used Weighted Gene Correlation
Network Analysis (WGCNA) R package for GCN module discovery [37,54] and WGCNA generates
large modules with hundreds to thousands of genes without being able to detect the smaller GCN
modules, suggesting that lmQCM is particularly suitable for discovering small overlapping GCN
modules with biological implications. This study is a particularly important and unique demonstration
of lmQCM’s ability to assign genes as components of multiple networks and how identification of
such genes may lead to important biological insights.
Though we focused on identifying co-expressed gene expression in response to fusion status
for this study, lmQCM analysis can also reveal important overall network differences in different
conditions. For example, the fusion negative gene correlation network had more, smaller modules
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compared to fusion positive. This suggests that either gene-level expression correlations were not
strong enough to merge smaller modules by lmQCM compared to FOXO1-PAX3/7.
Surprisingly, lmQCM network analysis of fusion positive samples also returned modules that
were differentially regulated between PAX3 and PAX7 fusions. This is an important contribution
to the literature about rhabdomyosarcoma because differences between fusion types are far less
studied than fusion presence more generally. Based on gene list enrichment, some of the genes
in differentially regulated modules have been reported by prior studies, e.g., 18 genes have been
previously associated PAX3 or PAX7 expression variance (Table S5). However, most of these genes
from differentially co-expression fusion positive modules reported no known responses to PAX3
or PAX7 in rhabdomyosarcoma or other cancers. Many, if not most, studies of FOXO1-PAX fusion
in rhabdomyosarcoma combine these two fusion subtypes, and few studies have PAX3 may differ
from PAX7. Here, we show that PAX3 vs PAX7 differences may be widespread to gene co-expression
with many of genes having higher expression levels in PAX7 (Figure 3). For example, FOXO1 and
PAX7 were both returned as differentially co-expressed in this analysis, which may have important
mechanistic explanations for differences between molecular subtypes. Interestingly, PAX7 fusion
caused an upregulation of BCL2—an apoptosis regulator—that was comparatively downregulated in
PAX3-type fusions. Prior reports have implicated BCL2 as a potential target for pharmaceuticals in
fusion positive rhabdomyosarcoma [55]. While further validation of this pattern is necessary, this may
suggest that apoptosis pathways have altered expression in fusion subtypes.
Importantly, many co-expression modules were not differentially regulated with respect to fusion
status (positive/negative), though there may be graphically distinct patterns that occur among samples
(Figure S2). Rhabdomyosarcoma is a diverse syndrome of rare cancers, so many other confounding
variables may influence the expression of these co-expressed genes such as stage, tissue of origin, tissue
heterogeneity, additional genetic mutations, or other markers of disease progression. Future studies
may seek to associate phenotypic, more comprehensive molecular, and clinical data with co-expression
modules from these rare diseases. Such investigations may find that disease prognosis, staging, and/or
mutational variance are associated with co-expression modules identified in the present study, which
were not associated with the FOXO1-PAX3/7 fusion.
5. Conclusions
The FOXO1-PAX3/7 fusion results in a novel transcriptional regulator that introduces novel
interactions among expressed genes. Prior studies have identified many genes that are differentially
regulated with respect the presence or absence of FOXO1-PAX3/7 gene fusion in rhabdomyosarcoma
using both experimental and clinical data. But the differential expression analyses that are commonly
used to identify fusion biomarkers are agnostic with respect to gene interactions. Here we show that
previously implicated genes are frequently co-expressed as networks of genes, raising the issue of
whether co-expressed genes are drivers or passengers. Our study importantly rediscovered differential
regulation of key apoptotic genes among co-expressed modules that have been previously targeted
by pharmaceutical development for rhabdomyosarcoma, though existing literature is limited. Future
work may consider how these pharmaceutical agents affect expression for gene co-expression networks
as identified in the present study. We also describe many genes that were differentially co-expressed
in PAX3 versus PAX7 fusions. While the FOXO1-PAX fusion has been well-studied, information
about differences between fusion types are generally limited. Here, we provide evidence of hereto
unexplored gene interaction networks that differ between fusion types. More importantly, modules
described herein provide evidence that FOXO1-PAX3/7 fusion affects not only differential expression
of individual genes, but also the interactions among them, which moves beyond the gene-by-gene
centric analyses that are commonly conducted. Future work could validate the differences identified
by network analysis as a means of discovering and understanding mechanistic differences among
fusion subtypes in rhabdomyosarcoma. Implementing a diversity of analytical approaches can lead
to exciting, new hypotheses regarding the functional and genetic roles of the FOXO1-PAX3/7 fusion
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in rhabdomyosarcoma, for which we plan to test experimentally using patient-derived cell and PDX
models. Such discoveries will shed light on the development of personalized treatment for this rare,
aggressive cancer, and promote similar research in other pediatric cancers.
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